Compare 10X Genomics Inc (TXG) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? 10X Genomics Inc trades at $82.23 (market cap $10.07B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.06 (market cap $3.80B). The key difference: 10X Genomics Inc is far larger — about 2.6× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| TXG | VNQI | |
|---|---|---|
Market Cap | $10.07B | $3.80B |
Volume | 5,657,286 | 277,049 |
Sector | Health | — |
52-Week High | $97.74 | $50.76 |
52-Week Low | $11.48 | $41.81 |
Typical Hold Time | 92 Days | 95 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
VNQI trades at $42.06, up 0.6% with a bearish technical signal from moving averages. The ETF focuses on international real estate across 30+ countries, offering diversification but facing recent price pressure below key moving averages. Short interest declined 45.9% in September (Defense World, 2026-10-02), potentially indicating reduced bearish sentiment despite the technical downtrend.
The outlook remains cautious given bearish technicals and international real estate exposure risks. Competitive advantages include lower expense ratios (0.12%) and higher dividend yields versus peers. Key risks involve global economic sensitivity and currency fluctuations affecting international holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
